RBC Capital downgrades Perspective Therapeutics to Sector Perform, sets price target to $4

What happened

RBC Capital downgraded Perspective Therapeutics to Sector Perform with a $4.00 price target, implying 148.4% upside from the October 23 close of $1.61. The analyst noted response rates in the VMT-α-NET program fell from 43% to 33% in key cohorts.

Confirmed

Global impact / market context

A downgrade changes how investors view the company's risk. Slower response rates weaken the drug's competitive position and could reduce future revenue, while a Phase III trial pushed to 2027 means more spending before any sales, raising the chance the company needs to raise more money.

Analyst inference

Even with the downgrade, the $4.00 target still implies large upside from $1.61, suggesting RBC sees value but less certainty. Investors may reassess how they size positions in early-stage biotech where trial timing and data quality drive returns and borrowing needs.

Analyst inference

What to watch

1. RBC set a $4.00 price target that implies 148.4% upside from the October 23 close of $1.61, a wide gap between the current price and the analyst's view of value. Confirmed
2. The company could face capital constraints because the Phase III trial start has been pushed to 2027, which means investors should watch for any plans to raise money or partner. Proposed
3. Further development and manufacturing capability needs add uncertainty to commercialization, so watch whether response rates improve and whether trial timing holds before committing capital. Analyst inference

Evidence

• Original source link unavailable